Immunodiagnostic Systems, the Newcastle based niche Diagnostics Company, announced that the final results to March 2011 showed sales of £50.2 million (2010: £37.2 million), pre-tax profit of £16.6 million (2010: £11.0 million), EPS of 41.1p (2010: 28.3p) and DPS of 2.5p (2010: 2.0p).
The company reported that Manual Vitamin D sales were £27.9 million (2010: £22.0 million) and IDS-iSYS sales were £10.4 million (2010: £2.7 million). Total Vitamin D sales grew 46% to £33.5 million, and whilst the growth in the Vitamin D market is expected to slow, it is still expected to more than double over the next five years. Gross margin was 74.7% (2010: 74.1%). Year end net cash was £61,000 (2010: £6.0 million net debt). Q1 2011/12 sales were £14.5 million (2010/11: £11.5 million), with instrument placings more than doubling.
In the June update it was reported that FDA clearance has been received for a further two of the IDS-iSYS assays, taking the FDA approved assays to five of the nine assays currently developed. This enables IDS to offer the first complete, fully automated Growth Panel in the US, which meets a clinical need and will further facilitate the placement of IDS-iSYS instruments in specialist laboratories.
The IDH share price has increased by 57% over the last year.
Immunodiagnostic Systems Holdings Plc is currently graded B by LCF Research. To learn more, follow this link.
